Drugs / Prevnar
Prevnar
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00164411 | Jan 2004 → Mar 2005 | pneumococcal infection | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00137605 | Sep 2004 → Oct 2007 | pneumococcal infection | CIHR Canadian HIV Trials Network | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00170612 | Nov 2005 → Jan 2008 | pneumococcal infection | University of Melbourne | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00109343 | Mar 2006 → Sep 2007 | measles, mumps infectious disease, rubella, varicella zoster infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00772928 | Oct 2003 → May 2006 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00197002 | Sep 2003 → Jan 2006 | hepatitis A virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 44 trials · 1 missed | ||||||
| Phase 4 | NCT00152802 | Jan 2005 → Jan 2009 | disease related to solid organ transplantation | University Health Network, Toronto | Unknown | Missed primary |
| Phase 4 | NCT00371878 | Feb → Oct 2003 | HIV infectious disease, meningitis, pneumococcal infection, pneumonia | Royal Liverpool University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00304382 | Jan 2003 → Sep 2006 | pneumococcal infection, pneumonia | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT00143780 | May 2002 → Jul 2006 | bone marrow disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01307449 | Apr 2014 → Jul 2017 | pneumococcal infection | Emory University | Completed | No outcome recorded |
| — | NCT00569309 | Dec 2007 → Jul 2011 | plasma cell myeloma, small intestine cancer | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Comparator or background therapy24 trials | ||||||
| Phase 1 | NCT06800261 Comparator | May 2025 → Jun 2026 overdue | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06562790 Comparator | Aug 2024 → Mar 2025 | streptococcal pneumonia | GPN Vaccines | Completed | No outcome recorded |
| Phase 1 | NCT01215175 Comparator | Sep 2009 → Apr 2010 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00834665 Background | Dec 2006 → Dec 2017 | plasma cell myeloma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1/2 | NCT01312389 Background | Apr 2011 → May 2012 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT07300644 Comparator | Nov 2025 → Sep 2026 overdue | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT01245673 Background | May 2011 → Dec 2015 | plasma cell myeloma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT01098474 Background | Jul 2010 → Apr 2011 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00861744 Background | Jun 2009 → Jul 2010 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00578175 Background | Nov 2007 → Feb 2009 | chickenpox, measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00323622 Comparator | Apr 2005 → May 2007 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00262002 Background | Sep 2004 → Jul 2005 | meningococcemia | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00129129 Background | Aug 2004 → Sep 2005 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00729001 Background | Nov 2000 → Sep 2002 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT06617715 Comparator | Oct 2024 → May 2026 overdue | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT01041573 Comparator | Mar 2010 → Feb 2011 | encephalitis | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00594347 Comparator | Nov 2007 → Mar 2008 | pneumococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00345683 Background | Jul 2007 → Sep 2008 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00457977 Comparator | Mar 2007 → May 2011 | chronic obstructive pulmonary disease | University of Minnesota | Completed | No outcome recorded |
| Phase 3 | NCT00401531 Background | Oct 2006 → Nov 2007 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT00289783 Background | Feb 2006 → Aug 2007 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00390130 Comparator | Jul 2006 → Jun 2007 | — | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 4 | NCT00312858 Comparator | Apr 2006 → Mar 2008 | hepatitis A virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00023504 Comparator | Jun 2002 → May 2017 | immunodeficiency disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded Stop: Enrollment |
Press releases naming this drug 11 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prevnar | “Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)” NCT00569309 ↗38“Pneumococcal Conjugate Vaccine (Prevnar; Wyeth) With Pneumococcal Polysaccharide Vaccine (23-valent) and Tetanus/Diphtheria Vaccine” NCT00164411 ↗ “Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion” NCT00834665 ↗ “Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants” NCT00401531 ↗ “heptavalent pneumococcal vaccine (PCV7; Prevnar(®), Pfizer)” PMID 25424793 ↗ 2014 “Prevnar® vaccine” NCT01098474 ↗ “PREVNAR™” NCT00109343 ↗ |
| Known as | PCV-7 | “This open-label, multicenter, randomized, comparative study evaluated immunogenicity, safety and tolerability of concomitant (Group 1; n=330) vs. non-concomitant (Group 2;...” PMID 23744509 ↗ Jun 20131“heptavalent pneumococcal vaccine (PCV7; Prevnar(®), Pfizer)” PMID 25424793 ↗ 2014 |
| Known as | Pneumococcal Conjugate Vaccine (PCV) | “Prevnar- Pneumococcal Conjugate Vaccine (PCV)” NCT01245673 ↗ |
| Modality | Vaccine | “using Pneumococcal vaccine immunization” NCT00023504 ↗ |
| Route | Intramuscular | “0.5-mL intramuscular injection” NCT00109343 ↗ |